

Resource Summary Report

Generated by [NIF](#) on Sep 18, 2026

Lu-65

RRID:CVCL_1392

Type: Cell Line

Proper Citation

RRID:CVCL_1392

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1392

Proper Citation: RRID:CVCL_1392

Description: Cell line Lu-65 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung giant cell carcinoma

Defining Citation: [PMID:3935627](#), [PMID:7116286](#), [PMID:8263009](#), [PMID:9290701](#), [PMID:9673367](#), [PMID:10536175](#), [PMID:11005564](#), [PMID:12068308](#), [PMID:12569360](#), [PMID:15746151](#), [PMID:16105816](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:22460905](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29444439](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38639832](#)

Comments: Population: Japanese., Part of: NCI RAS program mutant KRAS cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Lu-65

Synonyms: LU-65M, LU-65, LU65, Lu65, Lu 65, C-Lu-65, C-Lu65

Cross References: CLO:CLO_0050059, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:936, BioSample:SAMN03471065, BioSample:SAMN03472047, BioSample:SAMN10987648, cancercellines:CVCL_1392, Cell_Model_Passport:SIDM00547, CGH-DB:197-1, CGH-

DB:9183-4, ChEMBL-Cells:ChEMBL3308623, ChEMBL-Targets:ChEMBL614694, Cosmic:713875, Cosmic:716171, Cosmic:724863, Cosmic:733170, Cosmic:801584, Cosmic:808502, Cosmic:809127, Cosmic:844827, Cosmic:876175, Cosmic:889093, Cosmic:917989, Cosmic:929151, Cosmic:932930, Cosmic:946067, Cosmic:1066164, Cosmic:1219074, Cosmic:1239918, Cosmic:1571732, Cosmic:1995497, Cosmic:2125204, Cosmic:2668333, Cosmic-CLP:724863, DepMap:ACH-000438, EGA:EGAS00001000978, FANTOM5_SSTAR:10487-107B1, GDSC:724863, GEO:GSM827382, GEO:GSM887282, GEO:GSM888357, GEO:GSM1670067, IARC_TP53:11877, JCRB:JCRB0079, LiGeA:CCLE_344, LINCS_LDP:LCL-1904, PharmacDB:LU65_869_2019, PRIDE:PXD030304, Progenetix:CVCL_1392, PubChem_Cell_line:CVCL_1392, RCB:RCB1967, TKG:TKG 0442, Wikidata:Q54903206

ID: CVCL_1392

Record Creation Time: 20220427T220737+0000

Record Last Update: 20260913T004758+0000

Ratings and Alerts

No rating or validation information has been found for Lu-65.

No alerts have been found for Lu-65.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Stern YE, et al. (2026) Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. Cancer research, 86(2), 485.

Solanki HS, et al. (2026) RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer. Cancer research, 86(2), 467.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. Cancer cell.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell reports. Medicine, 5(6),

101578.

Janes MR, et al. (2018) Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. *Cell*, 172(3), 578.